Aliases & Classifications for Esophageal Disease

MalaCards integrated aliases for Esophageal Disease:

Name: Esophageal Disease 12 14
Esophageal Diseases 52 42 69
Ulcer of Esophagus 69
Esophageal Ulcer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6050
ICD10 33 K22.9
ICD9CM 35 530 530.9
MeSH 42 D004935
NCIt 47 C3027
UMLS 69 C0014852

Summaries for Esophageal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the esophagus.

MalaCards based summary : Esophageal Disease, also known as esophageal diseases, is related to lymphoma and deep angioma, and has symptoms including abdominal pain, constipation and coughing. An important gene associated with Esophageal Disease is ATP4A (ATPase H+/K+ Transporting Alpha Subunit), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Glucocorticoid receptor regulatory network. The drugs Octreotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and lymph node, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Wikipedia : 72 Esophageal diseases can derive from congenital conditions, or they can be acquired later in... more...

Related Diseases for Esophageal Disease

Diseases related to Esophageal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.8 IL13 IL5 TRPV1
2 deep angioma 10.8 TP53 WWOX
3 rhabdomyosarcoma 10.8 ATP4A HRH2
4 periodic limb movement disorder 10.8 ATP4A TEF
5 cryptogenic organizing pneumonia 10.7 ATP4A TEF TRPV1
6 cytoplasmic body myopathy 10.7 IL13 IL5
7 scrotal carcinoma 10.7 ATP4A HRH2
8 marasmus 10.7 IL5 TRPV1
9 aortic arch interruption 10.6 IL13 IL5
10 achalasia 10.6
11 scrotum squamous cell carcinoma 10.6 ATP4A CYP2C19
12 hypercementosis 10.6 IL13 IL5
13 toxic diffuse goiter 10.5 IL13 IL5
14 tendon sheath lipoma 10.5 PTGS2 TP53
15 paracoccidioidomycosis 10.5 ATP4A CYP2C19 TEF
16 esophagitis 10.5
17 scrotum melanoma 10.5 ATP12A ATP4A
18 ovarian melanoma 10.5 CDX2 WWOX
19 substance-induced psychosis 10.5 ATP4A GAST
20 congenital aphakia 10.5 ATP12A ATP4A
21 primary optic atrophy 10.5 TP53 WWOX
22 urethral calculus 10.5 ATP12A ATP4A
23 hypopituitarism 10.4 ATP12A ATP4A
24 amyotrophic lateral sclerosis type 5 10.4 ATP12A ATP4A
25 brain ependymoma 10.4 ATP4A HRH2 PTGS2
26 abnormal pupillary function 10.4 ATP12A ATP4A
27 lacrimal system cancer 10.4 IL13 IL5 TRPV1
28 atheroembolism of kidney 10.4 ATP12A ATP4A
29 microphthalmia, syndromic 12 10.4 ATP12A ATP4A
30 trachea leiomyoma 10.4 IL13 IL5 TSLP
31 synostosis 10.4 ATP12A ATP4A
32 dioctophymiasis 10.4 IL13 IL5
33 dentin caries 10.4 IL13 IL5 TSLP
34 fuchs' heterochromic uveitis 10.4 IL13 IL5 TSLP
35 polysyndactyly with cardiac malformation 10.3 ATP12A ATP4A
36 malignant epithelial mesothelioma 10.3 IL13 IL5 TRPV1
37 neovascular glaucoma 10.3 PTGS2 TP53 TRPV1
38 cushing's syndrome 10.3 ATP4A CDX2 PTGS2
39 cholesteatoma of middle ear 10.3 IL13 IL5
40 cloacal exstrophy 10.3 ATP12A ATP4A TEF
41 breast ductal adenoma 10.3 ATP12A ATP4A WWOX
42 intracranial hypertension 10.3 IL13 IL5 TSLP
43 adult xanthogranuloma 10.3 ATP12A ATP4A HRH2
44 proliferative fasciitis 10.2 ATP12A ATP4A
45 brown-vialetto-van laere syndrome 10.2 CDX2 TP53 TRPV1 WWOX
46 ragweed sensitivity 10.2 IL13 IL5 PTGS2
47 eyelid neoplasm 10.2 IL13 IL5 TRPV1 TSLP
48 dehydration polycythemia 10.2 IL13 IL5 TRPV1 TSLP
49 gastrointestinal neuroendocrine tumor 10.2 CDX2 PTGS2 TP53
50 spontaneous ocular nystagmus 10.2 IL13 IL5 TRPV1 TSLP

Comorbidity relations with Esophageal Disease via Phenotypic Disease Network (PDN): (show all 26)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Bronchitis
Chronic Kidney Failure Decubitus Ulcer
Deficiency Anemia Duodenitis
Dyskinesia of Esophagus Esophageal Cancer
Esophageal Candidiasis Esophageal Varix
Esophagitis Esophagus Carcinoma in Situ
Heart Disease Hypertension, Essential
Intestinal Obstruction Iron Deficiency Anemia
Ischemic Heart Disease Mallory-Weiss Syndrome
Megaesophagus Paralytic Ileus
Peptic Esophagitis Protein-Energy Malnutrition
Schizophreniform Disorder Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Disease:



Diseases related to Esophageal Disease

Symptoms & Phenotypes for Esophageal Disease

UMLS symptoms related to Esophageal Disease:


abdominal pain, constipation, coughing, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, signs and symptoms, digestive, snoring, sore throat, digestive system symptom, vertigo/dizziness, equilibration disorder, gastrointestinal gas

MGI Mouse Phenotypes related to Esophageal Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10 AAAS ATP12A ATP4A CDX2 GAST HRH2
2 homeostasis/metabolism MP:0005376 9.83 ATP4A CDX2 EPC2 GAST HRH2 IL13
3 endocrine/exocrine gland MP:0005379 9.81 AAAS ATP4A CDX2 GAST HRH2 IL13
4 neoplasm MP:0002006 9.17 CDX2 GAST IL5 PTGS2 TP53 TRPV1

Drugs & Therapeutics for Esophageal Disease

Drugs for Esophageal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 671)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4,Phase 1,Phase 2 83150-76-9 383414 6400441
2
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
3
Terlipressin Approved, Investigational Phase 4,Phase 3 14636-12-5 72081
4
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73590-58-6 4594
5
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3 57808-66-9 3151
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Pravastatin Approved Phase 4 81093-37-0 54687
8
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
9
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 1 525-66-6 4946
10
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
11
Budesonide Approved Phase 4,Phase 2,Phase 3 51333-22-3 63006 5281004
12
Dexlansoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138530-94-6, 103577-45-3 9578005
13
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103577-45-3 3883
14
Alginic acid Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1 9005-32-7
15
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Ethiodized oil Approved Phase 4,Phase 3 8008-53-5
17
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
18
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
19
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
20
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
21
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
22
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
23
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
24
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
25
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
26 Racepinephrine Approved Phase 4,Phase 2
27
Methylnaltrexone Approved Phase 4 83387-25-1, 916055-93-1 6603824
28
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 4,Phase 1 50-24-8 5755
31
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
32
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
33
Remifentanil Approved Phase 4 132875-61-7 60815
34
Ethanolamine Oleate Approved Phase 4,Phase 3 2272-11-9 5282489
35
Dinoprostone Approved Phase 4 363-24-6 5280360
36
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
37
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
38
Pectin Approved, Vet_approved Phase 4 9000-69-5 441476
39
Magnesium Hydroxide Approved Phase 4,Phase 3,Phase 1 1309-42-8
40
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
41
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
42
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 1 21645-51-2
43 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1 14987-04-3
44
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
45
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
46
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
47
Nicotine Approved Phase 4 54-11-5 942 89594
48
Ethanol Approved Phase 4 64-17-5 702
49
Dobutamine Approved Phase 4 34368-04-2 36811
50
Norepinephrine Approved Phase 4 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 2376)

id Name Status NCT ID Phase Drugs
1 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding Unknown status NCT00966355 Phase 4 Terlipressin;Somatostatin;Octreotide
2 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
5 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
6 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
7 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
8 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4 propranolol
9 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
10 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Unknown status NCT02371941 Phase 4 oral cromolyn sodium;Placebo
11 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4 Budesonide;Fluticasone
12 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
13 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
14 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
15 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
16 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
17 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
18 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
19 Opioids and Esophageal Function Completed NCT01012960 Phase 4 methylnaltrexone
20 Caustic Esophageal Burns in Children and High Doses of Methylprednisolone Completed NCT02002078 Phase 4 methylprednisolon
21 Opioid Effects on Swallowing and Esophageal Sphincter Pressure Completed NCT01191645 Phase 4 naloxone;remifentanil;Sodium Chloride;metoclopramide
22 Evaluation of Patients With Non-cardiac Chest Pain Completed NCT00476398 Phase 4
23 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
24 A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Completed NCT00799851 Phase 4 cyanoacrylate injection
25 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
26 Esophageal Fully Covered Metal Stents in Caustic Strictures Study Completed NCT01899300 Phase 4
27 PPI Sequencing Study Completed NCT00384592 Phase 4 Esomeprazole
28 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Completed NCT01874535 Phase 4 Esomeprazole 40 mg
29 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
30 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
31 Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
32 Barrett's Esophagus - 315 - 3 Way Cross-Over Completed NCT00637559 Phase 4 Esomeprazole Magnesium
33 Barrett's Esophagus - 315 - 3 Way Cross Over Completed NCT00637988 Phase 4 Esomeprazole;Aspirin;Rofecoxib
34 An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4 Esomeprazole;Lansoprazole
35 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
36 Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. Completed NCT01601379 Phase 4
37 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
38 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
39 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
40 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
41 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
42 Time Interval for Endoscopic Variceal Ligation Completed NCT01291277 Phase 4
43 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
44 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
45 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
46 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole
47 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
48 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
49 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
50 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole

Search NIH Clinical Center for Esophageal Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: esophageal diseases

Genetic Tests for Esophageal Disease

Anatomical Context for Esophageal Disease

MalaCards organs/tissues related to Esophageal Disease:

39
Lung, Testes, Lymph Node, Liver, T Cells, Breast, Bone

Publications for Esophageal Disease

Articles related to Esophageal Disease:

(show top 50) (show all 165)
id Title Authors Year
1
Evolution in the Treatment of Esophageal Disease at a Single Academic Institution: 2004-2013. ( 28486000 )
2017
2
Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease. ( 28437259 )
2017
3
Unsedated in Office Transgastrostomy Esophagoscopy (TGE) to Monitor Therapy in Pediatric Esophageal Disease. ( 28505050 )
2017
4
Can We Use Diet to Effectively Treat Esophageal Disease? A Review of the Current Literature. ( 28730507 )
2017
5
Incidence, reasons, and risk factors for readmission after surgery for benign distal esophageal disease. ( 27365228 )
2016
6
Emerging endoscopic techniques for the identification of esophageal disease. ( 26753504 )
2016
7
Palliation of Concomitant Tracheobronchial and Esophageal Disease Using a Combined Airway and Esophageal Approach. ( 27157053 )
2016
8
Literature Analysis of the Treatment of Benign Esophageal Disease with Stent. ( 27186033 )
2016
9
Functional lumen imaging probe: the functional lumen imaging probe side of esophageal disease. ( 27030931 )
2016
10
Understanding the sensory irregularities of esophageal disease. ( 26890720 )
2016
11
An unusual cause of dysphagia: Isolated IgG 4-related esophageal disease. ( 28000632 )
2016
12
Advances in the evaluation and management of esophageal disease of systemic sclerosis. ( 25475597 )
2015
13
Preface. Esophageal disease. ( 25965140 )
2015
14
Foreword. Esophageal disease. ( 25965139 )
2015
15
Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease. ( 25202116 )
2014
16
Diet and esophageal disease. ( 25266021 )
2014
17
Time trends of US hospitalization for esophageal disease. ( 24440940 )
2014
18
IgG4-Related Esophageal Disease Presenting as Esophagitis Dissecans Superficialis With Chronic Strictures. ( 24883156 )
2014
19
Esophageal disease. ( 23948187 )
2013
20
Eosinophilic esophagitis: an immune-mediated esophageal disease. ( 23579771 )
2013
21
Screening pre-bariatric surgery patients for esophageal disease with esophageal capsule endoscopy. ( 24115815 )
2013
22
Esophageal disease. ( 23990483 )
2013
23
Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. ( 24117631 )
2013
24
Redo laparoscopic repair of benign esophageal disease. ( 22608677 )
2012
25
Glycomic expression in esophageal disease. ( 24957772 )
2012
26
Comparison of 2 expandable stents for malignant esophageal disease: a randomized controlled trial. ( 22726466 )
2012
27
Expandable stents for malignant esophageal disease. ( 21684460 )
2011
28
Esophageal disease and pathology. ( 21950829 )
2011
29
Esophageal disease: updated information on inflammation. ( 21950828 )
2011
30
Expandable stents for benign esophageal disease. ( 21684459 )
2011
31
Fully covered self-expandable metal stents for benign esophageal disease: a multicenter retrospective case series of 31 patients. ( 21549373 )
2011
32
Esophageal disease in pediatrics. ( 21950832 )
2011
33
Surgical therapy for esophageal disease: lessons from a master. ( 20494006 )
2010
34
Helicobacter pylori and esophageal disease: wake-up call? ( 21029801 )
2010
35
This issue reviews all aspects of endosurgical technologies and devices that encompass endoluminal therapy for esophageal disease. Preface. ( 19951789 )
2010
36
High-resolution manometry: is it better for detecting esophageal disease? ( 21103442 )
2010
37
Endoluminal therapy for esophageal disease: an introduction. ( 19951790 )
2010
38
Recent advances in the use of stents for esophageal disease. ( 19951797 )
2010
39
The Mayo Dysphagia Questionnaire-30: documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease. ( 19856027 )
2010
40
Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. ( 19441788 )
2009
41
Benign esophageal disease in the elderly. ( 20066944 )
2009
42
Esophageal capsule endoscopy in patients with suspected esophageal disease: double blinded comparison with esophagogastroduodenoscopy and assessment of interobserver variability. ( 18058656 )
2008
43
Intestinal interposition for benign esophageal disease. ( 21063863 )
2008
44
Esophageal disease. Screening and surveillance for Barrett's esophagus: esophageal capsule versus conventional endoscopy. ( 18477971 )
2008
45
How to keep the treatment of esophageal disease in the surgeon's hands. ( 18222212 )
2008
46
Diagnosis and management of esophageal disease. ( 19107102 )
2008
47
Esophageal disease in progressive systemic sclerosis. ( 21063865 )
2008
48
Polyflex expandable stents in the treatment of esophageal disease: initial experience. ( 18498804 )
2008
49
Esophageal disease. Intragastric pH control and healing of erosive esophagitis. ( 18488271 )
2008
50
Detecting esophageal disease with second-generation capsule endoscopy: initial evaluation of the PillCam ESO 2. ( 18389444 )
2008

Variations for Esophageal Disease

Expression for Esophageal Disease

Search GEO for disease gene expression data for Esophageal Disease.

Pathways for Esophageal Disease

GO Terms for Esophageal Disease

Biological processes related to Esophageal Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.35 CCL26 IL13 IL5 PTGS2 TRPV1
2 microglial cell activation GO:0001774 9.32 IL13 TRPV1
3 cellular response to ATP GO:0071318 9.26 PTGS2 TRPV1
4 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
5 response to organonitrogen compound GO:0010243 8.8 CCL26 PTGS2 TRPV1

Molecular functions related to Esophageal Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CCL26 IL13 IL5 TSLP
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.16 ATP12A ATP4A
3 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophageal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....